SenzaGen granted its first patent for GARD potency biomarker test

Company can now offer an animal-free test method to quantify the strength of an allergenic effect.

The technology of SenzaGen's patent is implemented in the company's testing application, which for the first time makes it possible to measure the allergenicity of chemical substances, so-called potency classification, without animal research.

“Getting this patent approved for the European market is commercially interesting, as there is a ban within the EU on the sale of animal-tested cosmetic products. Furthermore, to quantify how strong the allergenic effect is according to CLP/GHS is a requirement in the EU chemical regulation REACH. As the only company in the world, SenzaGen can now offer an animal-free test method for this”, says Anki Malmborg Hager, CEO of SenzaGen.

SenzaGen’s IP strategy is to protect the company’s technology in all geographically important markets. Already granted in Europe, China and Hong Kong, patent applications for GARD skin are currently being processed by the patent authorities in countries where animal testing is prohibited or where a ban is expected to be introduced, including the US, Canada and India. In addition, the patent portfolio includes several ongoing patent applications for GARD potency and other GARD products.

SenzaGen’s GARD product portfolio consists of a set of allergy tests with industry-leading performance and accuracy. The tests are performed on human cells in test tubes (in vitro) in combination with artificial intelligence, and replace animal experiments for the cosmetics, chemical and pharmaceutical industries for their tests on whether chemical substances in products can be allergenic.